Modified virus takes on tough tumors in early trial
NCT ID NCT07262164
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called VG2062, a modified virus designed to attack cancer cells. It is for 30 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 67, Huayuan Road, Langfang Economic and Technological Development Zone, Hebei Province
RECRUITINGHebei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Oral drug elraglusib aims to tame advanced solid tumors
- Engineered virus targets Hard-to-Treat cancers from the inside
- Engineered herpes virus takes aim at Hard-to-Treat cancers
- Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
- New drug combo aims to shrink Hard-to-Treat tumors
- MRNA cancer shot shows promise in early trial